Clinical trial
A Phase 2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
NCT04245839 is registered in ClinicalTrials.gov with Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
- Lead sponsor
- Celgene
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- July 14, 2020
- Completion date
- September 30, 2031
- Enrollment
- 276 (estimated)
- Sites
- 49
Conditions
As the registry lists them; a condition with its own page is linked.